Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Cyclacel reports topline data from phase IIb APPRAISE trial of seliciclib

Dec. 22, 2010

Abbott divulges new inhibitors of IGF-I receptor

Dec. 22, 2010

LY-2784544 inhibits V617F-mutant JAK-2 signaling and advances through clinical development

Dec. 22, 2010

Nerviano Medical Sciences describes new inhibitors of PARP-1

Dec. 22, 2010

Exelixis patents novel PI3K-alpha/mTORC1 inhibitors

Dec. 22, 2010

Tasigna approved in Japan for newly diagnosed Ph+ CML

Dec. 21, 2010

New inhibitors of Aurora kinase A and B presented

Dec. 21, 2010

New inhibitors CK II and/or pim-1 discovered at Cylene Pharma

Dec. 21, 2010

FDA grants fast track status for elacytarabine in AML

Dec. 21, 2010

MRx-102 shows promise in models of AML

Dec. 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...